Navigation Links
Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
Date:9/22/2007

Legacy of Regulatory Submissions Leadership Strengthened with Clinical

Trials Services and Standards-Based Data Management

WHIPPANY, N.J. and ATLANTA, Sept. 6 /PRNewswire/ -- Image Solutions, Inc. (ISI) announced today it agreed to terms to acquire Zurich Biostatistics, Inc. (ZBI). With the Life Sciences industry moving to standards-based regulatory submissions, the acquisition further strengthens ISI's Clinical Data Interchange Standards Consortium (CDISC) capabilities, the FDA-supported standard for clinical trials data and metadata.

"The FDA's embrace of CDISC standards presents pharma and biotech companies with a once-in-a-decade opportunity to streamline processes and harmonize operations with submissions," said Jinsoo Kim, ISI president and chief executive officer. "Our portfolio of clinical trials services gains instant experience and credential with the acquisition of ZBI."

ZBI and its president, Michael Palmer, pioneered the development and implementation of CDISC-based regulatory submissions. Palmer has co-authored and contributed to CDISC standards since 2000. He will continue at ISI as vice president of biometrics, overseeing the company's CDISC products and services.

"Over the next year, the FDA will rapidly move towards data standardization as a way to expedite innovation and bring new drugs to market faster and more effectively, an issue the industry is finding much more difficult then it was five years ago," said Palmer. "The health and well-being of millions of people is at stake -- the streamlining of drug development has never been more important."

ISI's acquisition of ZBI also bolsters the company's new biometrics' service line. Securing FDA approval on new drug submissions frequently hinges on the analyses of biometrics data. With clinical trials costing drug sponsors hundreds of millions of dollars, failed submissions can be detrimental. By adding highly qualified and experienced statisticians and programmers, ISI is able to help clients create statistical plans, conduct analyses and assist in the preparation of reports to avoid these pitfalls. Companies are also able to achieve more effective collaboration between statisticians and medical writers, speeding time to final CSR.

ZBI's core capabilities in biometrics analysis support ISI's commitment to complete, holistic regulatory submissions. Existing clients of both ISI and ZBI now have instant access to this approach and capability.

ISI is a pioneer in modernizing the regulatory submission process. The company enabled the first-ever electronic new drug application to the FDA and is at the forefront of the industry's move to adopting the electronic Common Technical Document (eCTD), the new drug application standard that will be required by the FDA at the end of 2007.

About Image Solutions, Inc.

Founded in 1992, Image Solutions, Inc. (ISI) is a proven market leader in providing submissions solutions, process services and consulting to Life Sciences companies as a way to improve clinical and regulatory processes that bring new medicines to market. ISI was among the first professional services firm to deliver electronic submissions to the industry and since has delivered more than 1,000 electronic submissions and 400 eCTD submissions. ISI serves the top 50 pharmaceutical and biotech organizations as well as the top companies in other regulated industries.

ISI is a privately held company with headquarters in Whippany, New Jersey and operations throughout the U.S., Europe and Asia. ISI also remains committed to giving back to society and sharing its success with others by donating 10 percent of annual net profits to over 20 recognized charitable organizations. For more information, visit the company Web site at http://www.imagesolutions.com.

Press Contacts:

Lisa Meyer Kurt Rossler

Director, Global Marketing M Booth & Associates

973-560-0808 x. 217 212 481-7000

lisa.meyer@imagesolutions.com kurtr@mbooth.com


'/>"/>
SOURCE Image Solutions, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology news :

1. Image of myosin-actin interaction revealed in cover story of Molecular Cell
2. Key heart and Alzheimers disease protein imaged for first time in native state
3. New MRI technique quickly builds 3-D images of knees
4. Everything in its place: Researchers identify brain cells used to categorize images
5. With record resolution and sensitivity, tool images how life organizes in a cell membrane
6. Researchers image molecular motor structural changes
7. Detailed 3-D image catches a key regulator of neural stem cell differentiation in action
8. CSIRO imagery shows Outer Great Barrier Reef at risk from river plumes
9. Novel computed imaging technique uses blurry images to enhance view
10. Ultrasound upgrade produces images that work like 3-D movies
11. Researchers wake up viruses inside tumors to image and then destroy cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/9/2016)...  Perkotek an innovation leader in attendance control systems is proud to announce the ... employers to make sure the right employees are actually signing in, and to even ... ... ... ...
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
Breaking Biology Technology: